Aldosterone to active renin ratio is associated with nocturnal blood pressure in obese and treated hypertensive patients: The Styrian hypertension study

Journal of Clinical Hypertension

Volumn 16, Issue 4, 2014, Pages 289-294

  Grübler, Martin R ^a   Kienreich, Katharina ^a   Gaksch, Martin ^a   Verheyen, Nicolas ^a   Fahrleitner Pammer, Astrid ^a   Schmid, Johannes ^a   Grogorenz, Jana ^a   Ablasser, Klemens ^a   Pieske, Burkert ^a   Tomaschitz, Andreas ^a,b   Pilz, Stefan ^a,c  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b Specialist Clinic for Rehabilitation PV Bad Aussee   (Austria)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANTIHYPERTENSIVE AGENT; BRAIN NATRIURETIC PEPTIDE; HEMOGLOBIN A1C; HORMONE PRECURSOR; POTASSIUM; RENIN; SODIUM;

ADULT; AGE; ALDOSTERONE BLOOD LEVEL; ARTICLE; BODY MASS; DIASTOLIC BLOOD PRESSURE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBESITY; PLASMA RENIN ACTIVITY; POTASSIUM URINE LEVEL; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SALT INTAKE; SEX; SMOKING; SODIUM URINE LEVEL; SYSTOLIC BLOOD PRESSURE; AGED; AUSTRIA; BLOOD; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CIRCADIAN RHYTHM; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; STATISTICAL MODEL;

AGED; ALDOSTERONE; ANTIHYPERTENSIVE AGENTS; AUSTRIA; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; BODY MASS INDEX; CIRCADIAN RHYTHM; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERTENSION; LINEAR MODELS; MALE; MIDDLE AGED; OBESITY; RADIOIMMUNOASSAY; RENIN;

EID: 84898857415     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12274     Document Type: Article

References (43)

1. Tomaschitz A, Pilz S, Ritz E, et al. Aldosterone and arterial hypertension. Nat Rev Endocrinol. 2010;6:83-93.
2. Tomaschitz A, Pilz S, Ritz E, et al. Association of plasma aldosterone with cardiovascular mortality in patients with low estimated GFR: the Ludwigshafen Risk and Cardiovascular Health (LURIC) Study. Am J Kidney Dis. 2011;57:403-414.
3. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:3266-3281.
4. Gekle M, Grossmann C. Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly? Pflüg Arch Eur J Physiol. 2009;458:231-246.
5. Vasan RS, Evans JC, Larson MG, et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med. 2004;351:33-41.
6. Funder JW. The nongenomic actions of aldosterone. Endocr Rev. 2005;26:313-321.
7. Geerling JC, Loewy AD. Aldosterone in the brain. Am J Physiol Ren Physiol. 2009;297:559-576.
8. Huang BS, Wang H, Leenen FHH. Chronic central infusion of aldosterone leads to sympathetic hyperreactivity and hypertension in Dahl S but not Dahl R rats. Am J Physiol Heart Circ Physiol. 2005;288:517-524.
9. Batterink J, Stabler SN, Tejani AM, Fowkes CT. Spironolactone for hypertension. Cochrane Database Syst Rev. 2010;8:CD008169.
10. Chapman N, Dobson J, Wilson S, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49:839-845.
11. Václavík J, Sedlák R, Plachy M, et al. Addition of Spironolactone in Patients with Resistant Arterial Hypertension (ASPIRANT) a randomized, double-blind, placebo-controlled trial. Hypertension. 2011;57:1069-1075.
12. Calhoun DA, White WB. Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J Am Soc Hypertens. 2008;2:462-468.
13. Weber MA. Clinical implications of aldosterone blockade. Am Heart J. 2002;144:12-18.
14. White WB, Carr AA, Krause S, et al. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. Am J Cardiol. 2003;92:38-42.
15. Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens. 2002;15:709-716.
16. White WB, Calhoun DA, Krum H, et al. Blockade of aldosterone production as a novel approach to the management of high blood pressure: efficacy and tolerability of the aldosterone synthase inhibitor LCI699 in patients with stage 1-2 hypertension. J Am Coll Cardiol. 2010;55:582.
17. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159-2219.
18. Tomaschitz A, Maerz W, Pilz S, et al. Aldosterone/renin ratio determines peripheral and central blood pressure values over a broad range. J Am Coll Cardiol. 2010;55:2171-2180.
19. El-Gharbawy AH, Nadig VS, Kotchen JM, et al. Arterial pressure, left ventricular mass, and aldosterone in essential hypertension. Hypertension. 2001;37:845-850.
20. Kidambi S, Kotchen JM, Grim CE, et al. Association of adrenal steroids with hypertension and the metabolic syndrome in blacks. Hypertension. 2007;49:704-711.
21. Grim CE, Cowley AW Jr, Hamet P, et al. Hyperaldosteronism and hypertension: ethnic differences. Hypertension. 2005;45:766-772.
22. Pickering TG, Shimbo D, Haas D. Ambulatory blood-pressure monitoring. N Engl J Med. 2006;354:2368-2374.
23. Satoh M, Kikuya M, Hara A, et al. Aldosterone-to-renin ratio and home blood pressure in subjects with higher and lower sodium intake: the Ohasama Study. Hypertens Res. 2011;34:361-366.
24. Edelmann F, Tomaschitz A, Wachter R, et al. Serum aldosterone and its relationship to left ventricular structure and geometry in patients with preserved left ventricular ejection fraction. Eur Heart J. 2012;33:203-212.
25. Tomaschitz A, Pilz S. Aldosterone to renin ratio - a reliable screening tool for primary aldosteronism? Horm Metab Res. 2010;42:382-391.
26. Pilz S, Tomaschitz A, Stepan V, et al. Graz Endocrine Causes of Hypertension (GECOH) study: a diagnostic accuracy study of aldosterone to active renin ratio in screening for primary aldosteronism. BMC Endocr Disord. 2009;9:11.
27. Pilz S, Tomaschitz A, März W. Diagnostic procedures for primary aldosteronism/diagnostische methoden für den primären hyperaldosteronismus. LaboratoriumsMedizin. 2009;33:202-209.
28. Griffing GT, Wilson TE, Melby JC. Alterations in aldosterone secretion and metabolism in low renin hypertension. J Clin Endocrinol Metab. 1990;71:1454-1460.
29. Makhanova N, Hagaman J, Kim H-S, Smithies O. Salt-sensitive blood pressure in mice with increased expression of aldosterone synthase. Hypertension. 2008;51:134-140.
30. Putnam K, Shoemaker R, Yiannikouris F, Cassis LA. The renin-angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome. Am J Physiol Heart Circ Physiol. 2013;302:1219-1230.
31. Goodfriend TL, Calhoun DA. Resistant hypertension, obesity, sleep apnea, and aldosterone theory and therapy. Hypertension. 2004;43:518-524.
32. Bochud M, Nussberger J, Bovet P, et al. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension. 2006;48:239-245.
33. Burr ML, Dolan E, O'Brien EW, et al. The value of ambulatory blood pressure in older adults: the Dublin outcome study. Age Ageing. 2008;37:201-206.
34. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130:461-470.
35. Scott L, Woodiwiss AJ, Maseko MJ, et al. Aldosterone-to-renin ratio and the relationship between urinary salt excretion and blood pressure in a community of African ancestry. Am J Hypertens. 2011;24:951-957.
36. Du Cailar G, Fesler P, Ribstein J, Mimran A. Dietary sodium, aldosterone, and left ventricular mass changes during long-term inhibition of the renin-angiotensin system. Hypertension. 2010;56:865-870.
37. Jin Y, Kuznetsova T, Maillard M, et al. Independent relations of left ventricular structure with the 24-hour urinary excretion of sodium and aldosterone. Hypertension. 2009;54:489-495.
38. Tapolyai M, Uysal A, Dossabhoy NR, et al. High prevalence of Liddle syndrome phenotype among hypertensive US veterans in Northwest Louisiana. J Clin Hypertens. 2010;12:856-860.
39. Ritz E, Tomaschitz A. Aldosterone, a vasculotoxic agent-novel functions for an old hormone. Nephrol Dial Transplant. 2009;24:2302-2305.
40. Fulop T, Hickson DA, Wyatt SB, et al. Sleep-disordered breathing symptoms among African-Americans in the Jackson heart study. Sleep Med. 2012;13:1039-1049.
41. Funder J. Mineralocorticoid receptor antagonists for heart failure. Expert Opin Pharmacother. 2011;12:2767-2769.
42. Armanini D, Fiore C. Choice of diuretic therapy and reconsideration for aldosterone receptors blockers. Hypertension. 2010;55:5.
43. Thomas JP, Oake RJ. An accurate method for measurement of aldosterone production. Biochem J. 1969;115:109-111.